ImmunoBiochem Announces Multi-Target License and Option Agreement with ImmunoGen to Develop Next-Generation Antibody-Drug Conjugates
/PRNewswire/ - ImmunoBiochem Corporation, a privately-held biopharmaceutical company focused on the discovery of unique tumor targets and development of novel...